164 related articles for article (PubMed ID: 35678206)
21. Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sézary Syndrome.
Zic JA
Dermatol Clin; 2015 Oct; 33(4):765-76. PubMed ID: 26433848
[TBL] [Abstract][Full Text] [Related]
22. Mogamulizumab Forecast: Clearer Patients, with a Slight Chance of Immune Mayhem.
Larocca C; Kupper TS; LeBoeuf NR
Clin Cancer Res; 2019 Dec; 25(24):7272-7274. PubMed ID: 31615932
[TBL] [Abstract][Full Text] [Related]
23. CD30
Ellis A; Christensen LF; Sharma T; Meyerson H; Kord H; Cooper KD
J Am Acad Dermatol; 2021 Feb; 84(2):530-532. PubMed ID: 32437721
[No Abstract] [Full Text] [Related]
24. Clinical Characterization of Mogamulizumab-Associated Rash During Treatment of Mycosis Fungoides or Sézary Syndrome.
Hirotsu KE; Neal TM; Khodadoust MS; Wang JY; Rieger KE; Strelo J; Hong E; Kim YH; Kwong BY
JAMA Dermatol; 2021 Jun; 157(6):700-707. PubMed ID: 33881447
[TBL] [Abstract][Full Text] [Related]
25. State of the art therapy of mycosis fungoides and Sézary syndrome.
Kemme DJ; Bunn PA
Oncology (Williston Park); 1992 Feb; 6(2):31-42; discussion 44, 47-8. PubMed ID: 1532501
[TBL] [Abstract][Full Text] [Related]
26. New and established treatment options for mycosis fungoides and Sézary syndrome - an update.
Dugas-Breit S; Schulze HJ; Hallermann C
J Dtsch Dermatol Ges; 2014 Jul; 12(7):561-9. PubMed ID: 24889480
[TBL] [Abstract][Full Text] [Related]
27. Treatment of mycosis fungoides and Sézary syndrome with romidepsin: a series of 32 cases from the French Study Group for Cutaneous Lymphoma.
Deschamps O; Ram-Wolff C; Beylot-Barry M; Grange F; Skowron F; Dereure O; Boulinguez S; Aubin F; Ingen-Housz-Oro S; Bagot M;
Br J Dermatol; 2019 Feb; 180(2):423-424. PubMed ID: 30298903
[No Abstract] [Full Text] [Related]
28. Combination therapies for mycosis fungoides/Sézary syndrome: biologic rationale and recommendations.
Lewis DJ; Rook AH
Int J Dermatol; 2021 Sep; 60(9):e362-e364. PubMed ID: 33559132
[No Abstract] [Full Text] [Related]
29. Cyclosporine in the treatment of cutaneous T cell lymphoma.
Street ML; Muller SA; Pittelkow MR
J Am Acad Dermatol; 1990 Dec; 23(6 Pt 1):1084-9. PubMed ID: 2273106
[TBL] [Abstract][Full Text] [Related]
30. Current systemic therapeutic options for advanced mycosis fungoides and Sézary syndrome.
Janiga J; Kentley J; Nabhan C; Abdulla F
Leuk Lymphoma; 2018 Mar; 59(3):562-577. PubMed ID: 29308723
[TBL] [Abstract][Full Text] [Related]
31. Primary Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sezary Syndrome.
Querfeld C; Zain J; Rosen ST
Cancer Treat Res; 2019; 176():225-248. PubMed ID: 30596221
[TBL] [Abstract][Full Text] [Related]
32. The efficacy of vorinostat in combination with interferon alpha and extracorporeal photopheresis in late stage mycosis fungoides and Sezary syndrome.
Sanli H; Akay BN; Anadolu R; Ozcan M; Saral S; Akyol A
J Drugs Dermatol; 2011 Apr; 10(4):403-8. PubMed ID: 21455551
[TBL] [Abstract][Full Text] [Related]
33. Mogamulizumab and bexarotene are a promising association for the treatment of advanced cutaneous T-cell lymphomas: a case series.
Teoli M; Mandel VD; Franceschini C; Saraceni PL; Cicini MP; Ardigò M
Eur Rev Med Pharmacol Sci; 2022 Nov; 26(21):8118-8128. PubMed ID: 36394762
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of mogamulizumab in mycosis fungoides by patient blood involvement and time to response analysis in mycosis fungoides and Sézary syndrome: a post hoc analysis of the MAVORIC study.
Beylot-Barry M; Booken N; Weishaupt C; Medley M; Sun W; Rosen JP
Eur J Cancer; 2021 Oct; 156 Suppl 1():S47-S48. PubMed ID: 34649657
[No Abstract] [Full Text] [Related]
35. Treatment of advanced mycosis fungoides and Sézary syndrome with continuous infusions of methotrexate followed by fluorouracil and leucovorin rescue.
Schappell DL; Alper JC; McDonald CJ
Arch Dermatol; 1995 Mar; 131(3):307-13. PubMed ID: 7887660
[TBL] [Abstract][Full Text] [Related]
36. Pentostatin plus cyclophosphamide and bexarotene is an effective and safe combination in patients with mycosis fungoides/Sezary syndrome.
Calderon Cabrera C; de la Cruz Vicente F; Marín-Niebla A; Carrillo Cruz E; Rios Herranz E; Espigado Tocino I; Prats Martín C; Falantes JF; Martino Galiana ML; Perez-Simón JA
Br J Haematol; 2013 Jul; 162(1):130-2. PubMed ID: 23581433
[No Abstract] [Full Text] [Related]
37. Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sézary syndrome.
Ni X; Jorgensen JL; Goswami M; Challagundla P; Decker WK; Kim YH; Duvic MA
Clin Cancer Res; 2015 Jan; 21(2):274-85. PubMed ID: 25376389
[TBL] [Abstract][Full Text] [Related]
38. Vorinostat for refractory or relapsing epidermotropic T-cell lymphoma: a retrospective cohort study of 15 patients.
Kogge A; Volteau C; Saint-Jean M; Peuvrel L; Brocard A; Knol AC; Renaut JJ; Dréno B; Quéreux G
Acta Derm Venereol; 2015 Jan; 95(1):72-7. PubMed ID: 24806744
[TBL] [Abstract][Full Text] [Related]
39. The use of amitriptyline in mycosis fungoides.
Coe P
Palliat Med; 1999 May; 13(3):264. PubMed ID: 10474718
[No Abstract] [Full Text] [Related]
40. Systemic Treatment Options for Advanced-Stage Mycosis Fungoides and Sézary Syndrome.
Photiou L; van der Weyden C; McCormack C; Miles Prince H
Curr Oncol Rep; 2018 Mar; 20(4):32. PubMed ID: 29572582
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]